New insider activity at Celcuity ( (CELC) ) has taken place on December 3, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Richard E Buller recently sold 1,100 shares of Celcuity stock, amounting to a total transaction value of $107,943.
Recent Updates on CELC stock
In the last 24 hours, Celcuity Inc. announced the submission of its New Drug Application (NDA) for gedatolisib to the FDA, marking a significant milestone in its development of treatments for hormone receptor positive, HER2-negative, advanced breast cancer. This submission is based on promising results from the Phase 3 VIKTORIA-1 trial. Analysts have mixed views on Celcuity’s stock; Wolfe Research initiated coverage with an Outperform rating, citing the company’s potential as a top-tier acquisition target and the promising outlook for its PIK3CA-mt readout. Conversely, H.C. Wainwright downgraded the stock to Neutral, arguing that the shares are “priced for perfection” after a 608% year-to-date appreciation, suggesting more downside risk than upside at current levels. Celcuity’s recent earnings call highlighted strong clinical progress and a robust financial position, yet also noted increased financial losses and regulatory uncertainties that could impact future plans.
Spark’s Take on CELC Stock
According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.
Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.
To see Spark’s full report on CELC stock, click here.
More about Celcuity
YTD Price Performance: 642.57%
Average Trading Volume: 1,113,698
Technical Sentiment Signal: Buy
Current Market Cap: $4.51B